Shots:
- The EC has approved perioperative Imfinzi + FLOT for adults with resectable, early-stage & locally advanced (Stages II, III, IVA) G/GEJ cancers, based on P-III (MATTERHORN) trial; regulatory review is ongoing in Japan
- In the trial, Pts (n=948) received either Imfinzi (1500mg) + FLOT or PBO + FLOT for Q4W × 2 cycles, then surgery followed by Imfinzi or PBO for Q4W × 12 cycles, incl. 2 cycles of Imfinzi or PBO plus FLOT CT & 10 additional cycles of Imfinzi or PBO monotx.
- At interim analysis, the trial showed a 29% EFS improvement (mEFS not reached vs 32.8mos.), with EFS rates of 78.2% vs 74% at 1yr. & 67.4% vs 58.5% at 24mos. Final OS showed a 22% reduction in death risk, with 69% vs 62% alive at 3yrs. OS benefit continued to increase with longer follow-up, regardless of PD-L1 status
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca and Daiichi Sankyo’s Enhertu Receives US FDA Priority Review for HER2+ Early Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
